NCT05605964: An ongoing trial by Sumitomo Pharma Switzerland GmbH
This trial is ongoing. It must report results 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05605964 |
|---|---|
| Title | Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 25, 2023 |
| Completion date | Dec. 31, 2024 |
| Required reporting date | Dec. 31, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |